LipoMedix, a clinical-stage, oncology-focused pharmaceutical company involved in the development of cancer therapy based on a pegylated liposomal drug delivery platform, said that its lead compound, Promitil (PL-MLP), will be manufactured in the U.S. by ForDoz Pharma, a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products. 
 
Promitil’s formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. The compound consists of the liposome-based encapsulation of a new chemical entity called Mitomycin-c (MMC) lipidic prodrug (MLP), which is a proprietary prodrug form of the known anticancer agent MMC. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug-resistant tumors.
 
“We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a lower-toxicity and effective treatment option,” said Alberto Gabizon, president and chief scientific officer, LipoMedix. “We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz as we move toward Phase II studies to move the development of Promitil forward.”
 
By leveraging ForDoz’s drug delivery technology and experience, LipoMedix expects to be able to effectively troubleshoot the many industry-wide challenges of product development and manufacturing of nanotechnology.
 
“ForDoz has a proven track record in manufacturing and in successful commercialization,” said Sanjeev Luther, executive chairman of the board, LipoMedix. “Selecting the right partner for each step of the journey is critical to the strategic process of developing a drug and we believe ForDoz is that partner.”
 
James He, founder and chief executive officer, ForDoz, said, “Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer, better and easier lives. It was immediately apparent that the team at LipoMedix has patients top of mind, and we are proud to partner with them to manufacture Promitil here in the U.S.”